Quintiles, IMS Health complete merger

DANBURY, Conn. and RESEARCH TRIANGLE PARK, N.C. — Quintiles IMS on Monday announced that the merger between Quintiles Transnational Holdings and IMS Health has been completed. 

 

Shares of IMS Health were halted from trading Monday on the New York Stock Exchange and will no longer be traded. At the time of the effective merger, each IMS Health share was converted into 0.3840 shares of Quintiles stock. The combined company will be known as Quintiles IMS Holdings. 

 

“This combination addresses life-science companies’ most pressing needs: to transform the clinical development of innovative medicines, demonstrate the value of these medicines in the real world, and drive commercial success,” Quintiles CEO Tom Pike said when the merger was announced in May. “We are bringing together two best-in-class leaders. I’m confident that together we will make our clients even more successful.”